Preface

Volume 2 of Frontiers in Clinical Drug Research-Hematology comprises of five comprehensive chapters written by eminent experts covering recent advances in the treatment of lymphoma, bone marrow transplantation, chronic myeloid leukemia and various hematological malignancies.

In the first chapter Marfe and colleagues reviewed the literature related to molecular biology of chronic myeloid leukemia with particular emphasis on agents that target at the molecular level and their resistance mechanisms in order to combat disease.

The treatment of cancer by targeted biologics such as monoclonal antibodies has been shown to be a promising approach. According to recent studies, bi- and multi-specific antibodies have been found to be more effective in fighting against tumor cells. In the second chapter of this eBook, Stanglmaier and Hess present an overview of the current development of bi- and multi-specific antibodies for treatment of B-cell malignancies.

In the third chapter, Martín-Antonio et al., highlight the strengths and weaknesses of Natural Killer cells in fighting Multiple Myeloma and hematological malignancies. They also propose certain guidelines for the development of future trials.

Janousek and colleagues, in chapter 4, shed light on a potentially revolutionary topic i.e., nanoparticles and nanomaterials. They review the role of nanoparticles in the management of hematological and malignant disorders. Phipps and Teo in the last chapter have drawn attention to the importance of new advancements in delivery methods of Monoclonal Antibodies to target the antigens that are present on lymphoma cells.

I would like to acknowledge the efforts of all the contributors for their outstanding contributions. I am also thankful to the team of Bentham Science Publishers, especially Dr. Faryal Sami and Mr. Shehzad Naqvi led by Mr. Mahmood Alam, Director Bentham Science Publishers for their efforts.